ArticleArchives of medical science : AMS2012
Therapeutic options for severe asthma.
Article in Archives of medical science : AMS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between air pollution and allergic upper respiratory diseases: a meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Effect of outdoor air pollution on asthma exacerbations in children and adults: Systematic review and multilevel meta-analysis.PloS one · 2017Pooled it
- Trial
- Intranasal dupilumab improves responsiveness to steroid in an asthma mouse model.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Association of asthma genetic variants with asthma-associated traits reveals molecular pathways of eosinophilic asthma.Clinical and translational allergy · 2023Article
- Clinical profiles of patients referred for biological therapy and major limitations in the qualification paths in a specialist asthma centre.Postepy dermatologii i alergologii · 2023Article
- A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgGImmunotherapy advances · 2023Article
- The application of multi-omics in the respiratory microbiome: Progresses, challenges and promises.Computational and structural biotechnology journal · 2023Review
- Associations Between Gut Microbiota and Asthma Endotypes: A Cross-Sectional Study in South China Based on Patients with Newly Diagnosed Asthma.Journal of asthma and allergy · 2021Article
- miR-30a-3p participates in the development of asthma by targeting CCR3.Open medicine (Warsaw, Poland) · 2020Article
- The Role of the Microbiome in Asthma: The Gut⁻Lung Axis.International journal of molecular sciences · 2018Review
- Association of interleukin-17a rs2275913 gene polymorphism and asthma risk: a meta-analysis.Archives of medical science : AMS · 2018Review
- Eosinophilic Esophagitis: an Important Comorbid Condition of Asthma?Clinical reviews in allergy & immunology · 2018Review
- Bronchial hyperresponsiveness to mannitol, airway inflammation and Asthma Control Test in atopic asthmatic children.Archives of medical science : AMS · 2016Article
- Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland.Archives of medical science : AMS · 2015Article
- Pharmacotherapy of critical asthma syndrome: current and emerging therapies.Clinical reviews in allergy & immunology · 2015Review
- The acute management of asthma.Clinical reviews in allergy & immunology · 2015Review
- Omalizumab as a new therapeutic approach for children with severe asthma.Postepy dermatologii i alergologii · 2014Article
- Loss of asthma control after cessation of omalizumab treatment: real life data.Postepy dermatologii i alergologii · 2014Article
- Methotrexate as an oral corticosteroid-sparing agent in severe asthma: the emergence of a responder asthma endotype.European clinical respiratory journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the overall prevalence of asthma has escalated in the past decades, so has the population of patients with severe asthma. This condition is often difficult to manage due to the relative limitation of effective therapeutic options for the physician and the social and economic burden of the disease on the patient. Management should include an evaluation and elimination of modifiable risk factors such as smoking, allergen exposure, obesity and non-adherence, as well as therapy for co-morbidities like gastro-esophageal reflux disease and obstructive sleep apnea. Current treatment options include conventional agents such as inhalational corticosteroids, long acting β(2) agonists, leukotriene antagonists, and oral corticosteroids. Less conventional treatment options include immunotherapy with methotrexate, cyclosporine and tacrolimus, biological drugs like monoclonal antibodies, tumor necrosis factor-α blockers and oligonucleotides, phosphodiesterase inhibitors, antimicrobials and bronchial thermoplasty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.